Chrome Extension
WeChat Mini Program
Use on ChatGLM

PRAME and LEF1 in Combined Deep Penetrating Nevus and Combined Blue Nevus: Utility and Pitfalls.

AMERICAN JOURNAL OF DERMATOPATHOLOGY(2023)

Univ Texas MD Anderson Canc Ctr

Cited 0|Views35
Abstract
Deep penetrating nevi (DPN), particularly those showing combined features, or combined deep penetrating nevi (CDPN), may show histopathological resemblance to blue nevus (BN) and melanoma. Preferentially Expressed Antigen in MElanoma (PRAME) is a marker that helps distinguish melanoma from benign melanocytic lesions. Lymphoid enhancer-binding factor 1 (LEF1) has been proposed to be used in conjunction with & beta;-catenin for diagnosis of DPN. The immunohistochemical expression of PRAME and LEF1 was evaluated in 10 DPN (including 6 CDPN and 2 DPN-like proliferations with atypical features), 16 BN (including combined and cellular BN), and 2 melanomas with features of DPN or BN. PRAME was negative in most DPN (n = 10/10, n = 9/10, one case with discrepancy between readers) and all BN (n = 16/16), while the 2 melanomas included were positive (n = 2/2). All DPN were positive for LEF1 (n = 9/9) while only a subset of BN were positive (n = 6/16, P = 0.0028; n = 5/16, P = 0.001, per both readers). LEF1 seemed to be easier to interpret than & beta;-catenin because of its nuclear pattern of expression. The expression of LEF1 in the regular nevus component of combined BN presents a potential pitfall in practice because it may lead to misinterpretation of LEF1 as positive in the BN component of the lesion. However, a subset (approximately one-third) of combined BN seemed to show true LEF1 expression. Taking into account pitfalls in interpretation, the combinatorial panel of PRAME and LEF1, in addition to conventional histopathological features, may be useful to distinguish CDPN from combined BN and other benign and malignant mimics.
More
Translated text
Key words
deep penetrating nevus,blue nevus,melanoma,PRAME,LEF1
求助PDF
上传PDF
Bibtex
AI Read Science
AI Summary
AI Summary is the key point extracted automatically understanding the full text of the paper, including the background, methods, results, conclusions, icons and other key content, so that you can get the outline of the paper at a glance.
Example
Background
Key content
Introduction
Methods
Results
Related work
Fund
Key content
  • Pretraining has recently greatly promoted the development of natural language processing (NLP)
  • We show that M6 outperforms the baselines in multimodal downstream tasks, and the large M6 with 10 parameters can reach a better performance
  • We propose a method called M6 that is able to process information of multiple modalities and perform both single-modal and cross-modal understanding and generation
  • The model is scaled to large model with 10 billion parameters with sophisticated deployment, and the 10 -parameter M6-large is the largest pretrained model in Chinese
  • Experimental results show that our proposed M6 outperforms the baseline in a number of downstream tasks concerning both single modality and multiple modalities We will continue the pretraining of extremely large models by increasing data to explore the limit of its performance
Upload PDF to Generate Summary
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Related Papers
2019

被引用29 | 浏览

Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn
Chat Paper

要点】:研究探讨了PRAME和LEF1在区分深度穿透痣、混合型深度穿透痣与蓝痣及黑色素瘤中的效用和陷阱,发现联合使用这两个标记物有助于诊断。

方法】:通过免疫组化技术评估了PRAME和LEF1在10例DPN(包括6例CDPN和2例具有不典型特征的DPN样增生)、16例BN(包括混合型和细胞型BN)以及2例具有DPN或BN特征的黑色素瘤中的表达。

实验】:实验使用了10例DPN、16例BN和2例黑色素瘤样本,结果显示PRAME在大多数DPN和所有BN中均为阴性,而在2例黑色素瘤中均为阳性;所有DPN均表达LEF1,而只有部分BN表达LEF1。LEF1的表达模式较β-连环素更易解读,但其在混合型BN的常规痣成分中的表达可能导致误诊。综合考虑解读陷阱,PRAME和LEF1的联合检测可能有助于区分CDPN与混合型BN及其他良性或恶性模仿物。